BEAM (Beam Therapeutics) Other Long-Term Liabilities: $5.9 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BEAM Beam Therapeutics Inc BEAM
71 GF Score
Price $27.56
GF Value $28.11
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Beam Therapeutics Other Long-Term Liabilities?

Beam Therapeutics BEAM +1.16% 71 Other Long-Term Liabilities is $5.9 Mil as of Jun. 2026. GuruFocus rates BEAM with a GF Score™ of 71/100 and a GF Value™ of $28.11 (Fairly Valued). The stock has 4 warning signs investors should review.

Beam Therapeutics's other long-term liabilities for the quarter that ended in Jun. 2026 was $5.9 Mil.

Beam Therapeutics's quarterly other long-term liabilities declined from Dec. 2025 ($6.1 Mil) to Mar. 2026 ($5.8 Mil) but then increased from Mar. 2026 ($5.8 Mil) to Jun. 2026 ($5.9 Mil).

Beam Therapeutics's annual other long-term liabilities increased from Dec. 2023 ($3.0 Mil) to Dec. 2024 ($7.0 Mil) but then declined from Dec. 2024 ($7.0 Mil) to Dec. 2025 ($6.1 Mil).

Beam Therapeutics Other Long-Term Liabilities Related Terms

Beam Therapeutics Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Beam Therapeutics's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beam Therapeutics Other Long-Term Liabilities Chart

Beam Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only 37.17 13.84 3.02 7.04 6.13

Beam Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.04 13.63 6.13 5.75 5.88
BEAM
71GF Score
Beam Therapeutics Inc BEAM
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beam Therapeutics Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of $5.9 Mil mean?
Beam Therapeutics (BEAM) has a Other Long-Term Liabilities of $5.9 Mil as of Jun. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Beam Therapeutics and its competitors.
Is Beam Therapeutics' Other Long-Term Liabilities too high?
Beam Therapeutics' current Other Long-Term Liabilities is $5.9 Mil. Overall, Beam Therapeutics has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Beam Therapeutics' Other Long-Term Liabilities compare to KOD and TARS?
Beam Therapeutics' Other Long-Term Liabilities of $5.9 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Biotechnology company?
A good Other Long-Term Liabilities depends on the Biotechnology industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Beam Therapeutics and its competitors. Beam Therapeutics's current Other Long-Term Liabilities is $5.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beam Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Beam Therapeutics (BEAM) is currently considered Fairly Valued. The stock's GF Value™ is $28.11, compared to a current price of $27.56 — trading 2% below its estimated fair value. The current Other Long-Term Liabilities is $5.9 Mil. Beam Therapeutics' overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Beam Therapeutics (BEAM), the current Other Long-Term Liabilities is $5.9 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Beam Therapeutics (BEAM) Overvalued in 2026?

Based on GuruFocus' analysis, Beam Therapeutics stock appears to be undervalued. The current stock price of $27.56 is trading 2% below its estimated GF Value™ of $28.11. GuruFocus considers Beam Therapeutics to be Fairly Valued.

Key valuation signals for BEAM:

  • Other Long-Term Liabilities: $5.9 Mil
  • GF Value™: $28.11 vs. price of $27.56 (2% below fair value)
  • GF Score™: 71/100 with 4 warning signs

No single metric tells the full story. See the BEAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Beam Therapeutics Business Description

Other Exchanges BEAM:Mexico
Address 238 Main Street, Cambridge, MA, USA, 02142
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
71GF Score

Get the complete analysis for BEAM

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$27.56
Price
$28.11
GF Value